Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “MYCOSES”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,585 records · Page 88Linked to original sources
PubMed2005

[Genital mycoses].

Explore the source record for details and available documents.

Antifungal Agents↗
PubMed1992

Study on the sensitizing capacity of the new antimycotic sertaconazole in the treatment of cutaneous mycoses.

The sensitizing capacity of 7-chloro-3-[1-(2,4-dichlorophenyl)-2- (1H-imidazol-1-yl)ethoxy-methyl]benzo[b]thiophene (sertaconazole, FI-7045, CAS 99592-32-2) was studied in a randomized double-blind clinical trial in 78 atopical volunteers of both sexes. Sertaconazole in 2% dermatological cream form was compared with 5 other commercially available antimycotics (econazole, ketoconazole, bifonazole, clotrimazole and miconazole), using the excipient of the cream without sertaconazole and 2% sertaconazole in vaseline as controls. At the end of the trial, only miconazole showed a positive allergy (vesiculation) in two of the 78 individuals studied. The other substances did not demonstrate any sensitizing capacity, including sertaconazole and its excipient. This trial showed that sertaconazole in 2% dermatological cream form does not possess a sensitizing capacity for causing contact dermatitis which confirmed its excellent safety in topical use.

Adolescent↗
PubMed1992

Phase II study of the therapeutic efficacy and safety of the new antimycotic sertaconazole in the treatment of superficial mycoses caused by Candida albicans.

The activity of 7-chloro-3-[1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethoxy-methyl] benzo[b]thiophene (sertaconazole, FI-7045, CAS 99592-32-2) was studied in a randomized parallel double-blind clinical trial on 20 patients suffering from superficial mycosis caused by Candida albicans (confirmed microscopically and microbiologically). The patients were divided into two groups; one received sertaconazole 1% cream (10 patients) and the other received sertaconazole 2% cream (10 patients), over a period of 28 days. Clinical, microscopic and microbiological parameters were evaluated. Analytical parameters such as the appearance of possible undesirable effects (both local and general) were also monitored. The cure was total for 19 out of the 20 patients, demonstrating high efficacy. There were no relapses of infection in any of the cured patients. No local or general effects were recorded during the trial. The analytical parameters remained within normal limits. The clinical and microbiological cure, absence of relapses and the non-existence of local and general undesirable effects indicate that sertaconazole may represent an important advance in the therapy of superficial mycosis caused by Candida albicans.

Adult↗
PubMed1992

Multi-centre double-blind trial on the efficacy and safety of sertaconazole 2% cream in comparison with miconazole 2% cream on patients suffering from cutaneous mycoses.

The efficacy and tolerance of 7-chloro-3-[1-(2,4-dichlorophenyl)-2- (1H-imidazol-1-yl)ethoxy-methyl]benzo[b]thiophene (sertaconazole, FI-7045, CAS 99592-32-2) 2% dermatological cream in two daily applications compared with miconazole 2% cream in two daily applications were studied on 631 patients suffering from superficial cutaneous mycosis (sertaconazole n = 317, miconazole n = 314), in a double-blind, controlled multicentre trial with parallel groups. The therapeutic efficacy was evaluated by clinical assessment of the improvement of the lesion and symptoms, a microscopic test on the presence of hyphae or mycelia in the affected area and a culture test on the presence of active infection. Tolerance and safety were evaluated by a general blood analysis and interrogation of the patient on adverse effects. The rate of clinical cures for both treatments at the end of the follow-up was 95.6% for sertaconazole and 88.1% for miconazole, with the difference being statistically significant. In the comparative analysis of the actuarial curve, it was observed that the patients treated with sertaconazole were cured earlier and in a higher proportion than those treated with miconazole, with the difference being significant. The negative result of the microscope examination and culture test confirmed the superiority of sertaconazole over miconazole, already after 14 days of treatment. At the end of the follow-up, 98.6% of the patients in the sertaconazole group obtained a negative culture test result, as opposed to 91.7% in the miconazole group, with the difference being highly significant.(ABSTRACT TRUNCATED AT 250 WORDS)

Administration, Topical↗
PubMed1997

Treatment of superficial mycoses.

Superficial fungal infection of the skin is treated with the help of systemic and topical medicaments. Commonly used drugs include griseofulvin, Ketoconazole and terbinafine. The drugs have undergone a wide research. In the following these drugs have been discussed.

Journal Article↗
PubMed1991

A clinico-radiological study of secondary mycoses in pulmonary tuberculosis.

Clinical and radiological differences were compared in Fungus positive (74) and negative (66) cases of pulmonary tuberculosis. Cough, expectoration, dyspnoea, and fever were marked in former group than that of latter. Anaemia, leucocytosis, raised ESR, abnormal radiological shadows and mycetoma in healed cavity were also noted in significant number in fungus positive cases.

Calcinosis↗
PubMed1991

[Mucoraceae mycoses: clinical aspects and pathology in ten patients].

Zygomycosis is characterized by a very high lethality, often favoured by rapid fungal growth in blood vessels causing the formation of thrombi and infarcts in several organs, a disease poor in symptoms. A disseminated mycosis normally is a complication of a granulocytopenia which is in our days more frequently observed as localized manifestation, whereas the typical rhinocerebral manifestation complicating diabetic ketoacidosis has become more rare. The diagnosis of zygomycosis can apparently be obtained easier by histology than by culture. The prognosis of zygomycosis can be improved by: 1. an early examination by biopsy, 2. if possible a rapid correction of predisposing factors (e.g. correction of acidosis), 3. an early antimycotic therapy by amphotericin B in risk patients, even if no causative agent can be cultured.

Acidosis↗
PubMedDate not supplied

[Correlations between culture methods, double diffusion and immunofluorescence in the laboratory diagnosis of mycoses (candidiasis and aspergillosis)].

Of a total of 1950 patients with various pneumologic affections 115 cases were selected, on the basis of positive mycologic results on examination of the bronchial aspirate. In these patients immunodiffusion and immunofluorescence serological tests were carried out. Confrontation with the clinical and histopathologic diagnosis showed that the simultaneous use of mycological studies (of the bronchial aspirate) and of complex serologic investigations (immunodiffusion, immunofluorescence) allow to make a correcs and aspergilloses.

Aspergillosis↗